- Celcuity strengthens case for ASCO-spotlighted breast cancer drug<figure><div><img src="https://imgproxy.divecdn.com/1TNhYQTUI7yObB637nFZIAJqv_C_vHe6B8CqUtpkWHg/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMTQwMTQ3MDc2LmpwZ…BioPharma Dive · 2mo ago↗ source
- Supreme Court restores mifepristone access by mailThe Supreme Court restored mail ordering of mifepristone, reversing a federal appeals court’s stay. The decision Monday came after makers of the pill asked for an immediate response to a ruling ...Endpoints · 2mo ago↗ source
- Celcuity's breast cancer win; Odyssey plans $205M IPOCelcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its Phase 3 trial. Last year ...